BofA update shows where active managers are putting money
KELOWNA, BC - Lexaria Bioscience Corp. (NASDAQ:LEXX) has announced preliminary results from its ongoing animal study, which indicate that its DehydraTECH-liraglutide formulation is outperforming its semaglutide counterpart in terms of weight loss efficacy. The study, which began on an unspecified date, is unique in evaluating the performance of liraglutide processed with Lexaria's proprietary DehydraTECH technology.
The study utilized diabetic, pre-conditioned Zucker rats and is expected to last for 12 weeks following an initial acclimation period. Over 1,500 blood plasma samples will be collected for pharmacokinetic analysis. It is important to note that the small number of animals in each study arm means statistical significance is not anticipated, and the study's primary value is in comparing the relative performance of the different groups.
During the first 28 days, DehydraTECH-CBD groups B and C demonstrated superior performance compared to all groups treated with Rybelsus and semaglutide, regardless of the use of SNAC technology. The study's results are based on the percentage change in body weight from the beginning of the dosing period to days 28 and 56.
The company cautions readers against comparing these animal study results to human weight loss studies due to the unlimited food and water provided to the animals, which can lead to morbid obesity. The study's focus is on the relative performance of the different groups to provide directional evidence for future research.
Lexaria's DehydraTECH is a patented drug delivery platform designed to improve the bio-absorption of active pharmaceutical ingredients through oral delivery. The company has developed the technology since 2016 and has demonstrated its potential to enhance drug delivery across the blood-brain barrier.
The ongoing study is part of Lexaria's broader research initiatives, and additional results are anticipated. It's important to acknowledge that the information in this article is based on a press release statement from Lexaria Bioscience Corp.
In other recent news, Lexaria Bioscience Corp. has reported progress in its ongoing diabetes control study, indicating potential benefits in diabetes management through its DehydraTECH technology. The company also announced positive outcomes from a joint research program with the National Research Council of Canada, focusing on the DehydraTECH technology's effectiveness in processing the GLP-1 drug, semaglutide. In addition, Lexaria Bioscience has expanded its management team, appointing Nelson Cabatuan as the consulting Chief Strategic Financial Advisor, and has acquired two significant patents pertaining to the treatment of hypertension and epilepsy. H.C. Wainwright has maintained its Buy rating for Lexaria Bioscience, highlighting the potential of the DehydraTECH technology to significantly impact obesity and diabetes treatment. These developments underscore the company's ongoing commitment to research and innovation in the pharmaceutical sector.
InvestingPro Insights
Lexaria Bioscience Corp. (NASDAQ:LEXX) has recently showcased promising preliminary results from its animal study, potentially impacting its financial outlook. InvestingPro data highlights a market capitalization of $52.02 million, reflecting the company's current valuation in the market. Despite not being profitable in the last twelve months, analysts are optimistic about Lexaria's sales growth prospects in the current year. This anticipation is supported by a revenue growth of 34.05% in the last twelve months as of Q3 2024, indicating a positive trajectory for the company's top-line performance.
Moreover, with a gross profit margin of 98.83% in the same period, Lexaria demonstrates its ability to maintain a high level of profitability on its products sold. This is a critical factor for investors considering the company's financial health and operational efficiency. Additionally, the InvestingPro Tips suggest that Lexaria holds more cash than debt on its balance sheet, which is a reassuring sign of financial stability for potential and current investors. This is further complemented by the company's liquidity position, where its liquid assets exceed short-term obligations, ensuring that Lexaria can meet its immediate financial responsibilities.
While the company's P/E ratio stands at -7, indicating that it is not currently profitable, the strong returns over the past year, with a year-to-date price total return of 163.2% and a one-year price total return of 207.48%, suggest that investors are confident in Lexaria's potential. These returns are reflective of the market's response to the company's strategic initiatives and technological advancements like the DehydraTECH platform.
For those interested in a deeper analysis, there are additional InvestingPro Tips available, which can provide further insights into Lexaria's financial and operational metrics. As of now, there are 10 more tips listed on InvestingPro that can help investors make an informed decision about their interest in Lexaria Bioscience Corp.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.